Elusys Therapeutics Finalizes HHS Contract to Deliver ANTHIM®, Its Treatment for Inhalation Anthrax, to the U.S. Department of Health and Human Services Jan 31, 2022
Heat Biologics Announces New PTX-35 Preclinical Data in Organ Transplantation and Provides Update on HS-110 Jan 12, 2022
Heat Biologics Unveils RapidVax®, A Novel Cellular Vaccine Platform Targeting Known and Unknown Emerging Biological Threats Nov 30, 2021
Heat Biologics Appoints Paul Tebbey as Senior Vice President of Product Development and Portfolio Strategy Oct 6, 2021
Heat Biologics CEO to Present at the Cantor Fitzgerald Global Healthcare Conference on September 29th Sep 15, 2021
Heat Biologics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference Sep 9, 2021
